Effect of nucleotides on translocation of sugar nucleotides and adenosine 3'-phosphate 5'-phosphosulfate into Golgi apparatus vesicles.
Recent studies from this laboratory have suggested that rat-liver Golgi apparatus derived membranes contain different proteins which can translocate in vitro CMP-N-acetylneuraminic acid, GDP-fucose and adenosine 3'-phosphate 5'-phosphosulfate from an external compartment into a lumenal one. The aim of this study was to define the role of the nucleotide, sugar and sulfate moieties of sugar nucleotides and adenosine 3'-phosphate 5'-phosphosulfate in translocation of these latter compounds across Golgi vesicle membranes. Indirect evidence was obtained suggesting that the nucleotide (but not sugar or sulfate) is a necessary recognition feature for binding to the Golgi membrane (measured as inhibition of translocation) but is not sufficient for overall translocation; this latter event also depends on the type of sugar. Important recognition features for inhibition of translocation of the above sugar nucleotides and adenosine 3'-phosphate 5'-phosphosulfate were found to be the type of nucleotide base (purine or pyrimidine) and the position of the phosphate group in the ribose. Thus, UMP and CMP were found to be competitive inhibitors of translocation of CMP-N-acetylneuraminic acid, while AMP did not inhibit. Structural features of the nucleotides which were less important in inhibition of translocation (and thus presumably in binding) of the above sugar nucleotides and adenosine 3'-phosphate 5'-phosphosulfate were the number of phosphate groups in the nucleotide (CDP and CMP inhibited to a similar extent), the presence of ribose or deoxyribose in the nucleotide, a replacement of hydrogen in positions 5 of pyrimidines or 8 in purines by halogens or an azido group. The sugar or sulfate did not inhibit translocation of the above sugar nucleotides and adenosine 3'-phosphate 5'-phosphosulfate into Golgi vesicles and therefore appear not to be involved in their binding to the Golgi membrane.
D000227:Adenine Nucleotides / Q000378:metabolism* / Q000494:pharmacology; D000818:Animals; D001667:Binding, Competitive; D001692:Biological Transport / Q000187:drug effects; D003568:Cytidine Monophosphate / Q000494:pharmacology; D003569:Cytidine Monophosphate N-Acetylneuraminic Acid / Q000378:metabolism*; D006056:Golgi Apparatus / Q000378:metabolism*; D006150:Guanine Nucleotides / Q000494:pharmacology; D006154:Guanosine Diphosphate Fucose / Q000378:metabolism*; D008099:Liver / Q000378:metabolism*; D009702:Nucleoside Diphosphate Sugars / Q000378:metabolism*; D009711:Nucleotides / Q000494:pharmacology*; D010724:Phosphoadenosine Phosphosulfate / Q000378:metabolism*; D051381:Rats; D012794:Sialic Acids / Q000378:metabolism*; D013329:Structure-Activity Relationship; D014542:Uridine Monophosphate / Q000494:pharmacology
D000227:Adenine Nucleotides; D006150:Guanine Nucleotides; D009702:Nucleoside Diphosphate Sugars; D009711:Nucleotides; D012794:Sialic Acids; D006154:Guanosine Diphosphate Fucose; D003569:Cytidine Monophosphate N-Acetylneuraminic Acid; D010724:Phosphoadenosine Phosphosulfate; D014542:Uridine Monophosphate; D003568:Cytidine Monophosphate